Semaglutide Explained: The Science Behind the Weight Loss Peptide

What Is Semaglutide?

Semaglutide is a synthetic peptide — a chain of amino acids — that mimics a naturally occurring gut hormone called glucagon-like peptide-1 (GLP-1). Your body produces GLP-1 in the small intestine within minutes of eating. Its job is to tell your pancreas to release insulin, tell your liver to stop dumping glucose into the blood, slow down how fast food leaves your stomach, and send a "I'm satisfied" signal to the brain.

The problem with natural GLP-1 is that it breaks down in about two minutes. Semaglutide was engineered — by Danish pharmaceutical company Novo Nordisk — to last much longer. Through modifications to the peptide structure and the addition of a fatty acid chain, the half-life was extended to roughly one week. That's why it's dosed as a once-weekly injection (or, in the oral form, once daily).

The GLP-1 receptor agonist class

Semaglutide belongs to a drug class called GLP-1 receptor agonists (GLP-1 RAs). It's not the first — liraglutide (Victoza/Saxenda) and exenatide (Byetta) came before it — but it is currently among the most potent. It binds to GLP-1 receptors throughout the body: in the pancreas, gut, liver, heart, and, critically, the brain.

Semaglutide was first approved as a diabetes medication (under the brand name Ozempic) in 2017, then in a higher dose specifically for weight management (Wegovy) in 2021. An oral tablet version (Rybelsus) exists for diabetes management but is less commonly prescribed for weight loss due to lower bioavailability.

How It Works for Weight Loss

Semaglutide doesn't work through a single mechanism. Weight loss is a downstream effect of several simultaneous changes in biology — which is part of why the results in clinical trials have been more significant than most prior weight loss medications.

1. Appetite suppression via the brain

The most significant mechanism for weight loss isn't in the gut — it's in the hypothalamus and brainstem, regions of the brain that regulate hunger and satiety. GLP-1 receptors in these areas, when activated by semaglutide, reduce the motivation to eat, decrease food cravings (particularly for high-calorie foods), and increase the sensation of fullness after smaller portions.

Many people taking semaglutide report that they simply think about food less. "Food noise" — the persistent mental preoccupation with eating — is reduced. This isn't willpower. It's neurochemistry.

2. Slowed gastric emptying

Semaglutide slows how quickly food moves from the stomach into the small intestine. This delays the absorption of calories and carbohydrates, blunts post-meal glucose spikes, and extends the feeling of fullness after eating. It's a direct contributor to both the weight loss and glucose-lowering effects.

3. Improved insulin sensitivity

By stimulating insulin secretion in a glucose-dependent manner (only when blood sugar is elevated), semaglutide improves how efficiently the body uses glucose. This is particularly relevant for people with type 2 diabetes or prediabetes, and may contribute to fat loss independently of reduced caloric intake by improving how the body partitions energy.

4. Potential direct metabolic effects

Emerging research suggests semaglutide may also act directly on fat tissue and the liver, reducing lipogenesis (fat creation) and improving liver fat content. These effects are still being studied, but they may explain why metabolic improvements in clinical trials sometimes exceeded what calorie reduction alone would predict.

FDA-Approved vs. Off-Label Uses

Semaglutide currently has three FDA-approved products in the United States, each with different indications and dose ranges.

Off-label prescribing

Ozempic is frequently prescribed off-label for weight loss in people without diabetes — a practice that has contributed to widespread shortages. This is legal; physicians can prescribe any approved medication for any purpose they deem clinically appropriate. However, insurance coverage for off-label use is typically denied, meaning out-of-pocket costs apply.

Compounded semaglutide became widely available from compounding pharmacies during the period of FDA-declared drug shortage. The FDA has stated that compound versions are not FDA-approved and their safety, sterility, and potency cannot be guaranteed. The agency has moved to restrict compounding as shortage designations are lifted.

What Clinical Trials Actually Show

The clinical evidence for semaglutide's weight loss effects is substantial — and more compelling than most prior weight loss medications. Here's what the pivotal data shows.

The STEP trials (Wegovy approval basis)

The STEP (Semaglutide Treatment Effect in People with obesity) program was a series of Phase 3 trials that supported Wegovy's approval. STEP 1, the largest, enrolled 1,961 adults with obesity or overweight without diabetes. At 68 weeks:

• Average weight loss: ~15% of body weight in the semaglutide group vs. ~2.4% in the placebo group
• 86% of participants lost ≥5% of body weight (vs. 32% with placebo)
• 50% lost ≥15% of body weight (vs. 5% with placebo)
• 30% lost ≥20% of body weight

These are averages — individual responses varied considerably. Some participants lost over 25% of body weight; others lost less than 5%.

SUSTAIN trials (Ozempic basis) & cardiovascular data

The SUSTAIN trials established Ozempic's efficacy for type 2 diabetes. Separately, the SELECT trial (2023) — enrolling over 17,000 adults with cardiovascular disease but without diabetes — found that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% over 3.3 years. This led to an expanded FDA approval for cardiovascular risk reduction in 2024.

What happens when you stop?

The STEP 4 withdrawal trial followed participants who stopped semaglutide after 20 weeks of treatment. Over the next 48 weeks, they regained approximately two-thirds of their lost weight. Cardiometabolic markers also worsened. This is consistent with the mechanism: semaglutide is treating an ongoing biological condition (reduced GLP-1 signaling), not fixing an underlying cause. Current evidence suggests it is a long-term or indefinite treatment for most people.

Side Effects & Safety Considerations

Semaglutide has a well-characterized safety profile from large clinical trials and post-market surveillance. It is not benign, and the side effects profile deserves honest discussion.

Common side effects (gastrointestinal)

GI side effects are by far the most frequently reported and are the primary reason people discontinue treatment. In STEP 1, among semaglutide participants:

• Nausea: ~44% (vs. ~16% placebo)
• Diarrhea: ~30% (vs. ~16% placebo)
• Vomiting: ~24% (vs. ~6% placebo)
• Constipation: ~24% (vs. ~11% placebo)

These effects are dose-dependent and typically peak during dose escalation. Most improve significantly after 4–12 weeks. Eating smaller meals, avoiding high-fat foods, and eating slowly can help manage GI symptoms. Approximately 7% of participants in STEP 1 discontinued due to GI side effects.

Muscle mass loss

A significant concern, supported by trial data, is that a meaningful portion of weight lost with semaglutide is lean muscle mass rather than fat exclusively. Estimates vary, but some analyses suggest lean mass may represent 25–40% of total weight lost, depending on protein intake and physical activity level. This is more pronounced than surgical weight loss interventions in some comparisons.

Adequate protein intake (1.2–1.6 g/kg of body weight) and resistance exercise during treatment are widely recommended to mitigate lean mass loss, though rigorous data specific to semaglutide users is still emerging.

Serious but less common risks

Semaglutide vs. Tirzepatide: A Brief Comparison

Tirzepatide (brand names Mounjaro for diabetes, Zepbound for weight management) is a newer medication that has drawn frequent comparisons to semaglutide. The key structural difference: tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor simultaneously. Whether dual agonism is meaningfully superior for weight loss is the central question.

Head-to-head trial data from the SURMOUNT-5 trial (2024) confirmed that tirzepatide produced approximately 47% greater relative weight loss compared to semaglutide in adults with obesity. That said, both medications produce meaningful weight loss for most users, individual responses vary, and semaglutide has a longer safety track record. The "better" choice depends on individual health history, cardiovascular needs, tolerability, and cost — a conversation for you and your physician.

Cost and Accessibility

Cost is one of the most significant practical barriers to semaglutide access, particularly in the United States.

List prices and insurance coverage

Wegovy's list price is approximately $1,350 per month without insurance. Insurance coverage for weight management indications remains inconsistent. Medicare Part D did not cover weight loss drugs until CMMI's Wegovy pilot in 2024, and private insurance coverage varies widely by plan and employer. Coverage is more predictable for the Ozempic formulation in patients with a diabetes diagnosis.

Manufacturer savings cards (Novo Nordisk offers a $0 copay program for eligible commercially insured patients) can dramatically reduce out-of-pocket costs for those with qualifying insurance. Check novo-pi.com for current programs.

The compounding question

During the 2022–2024 shortage period, compounded semaglutide from licensed compounding pharmacies became widely available at prices ranging from $150–$500/month, driving a significant expansion in access. The FDA has since issued guidance on when compounding is no longer permissible as shortages resolve. If you're considering a compounded version, verify the pharmacy's PCAB accreditation and discuss the regulatory status with your provider.

Global access disparities

Outside the US, pricing and coverage differ substantially. In Canada, the UK (NHS), Germany, and most of the EU, Ozempic is widely covered for diabetes. Wegovy coverage for obesity is more variable and has faced access restrictions in several countries due to supply constraints and health technology assessment outcomes.

What to Know Before Considering Semaglutide

If you're weighing whether semaglutide might be appropriate for you, here are the practical considerations worth discussing with a healthcare provider — not as a checklist to self-diagnose, but as a framework for an informed conversation.

Who tends to be a candidate

Current FDA-approved criteria for Wegovy: adults with a BMI of 30 or higher (obesity), or 27 or higher (overweight) with at least one weight-related condition such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea. Physicians can also prescribe based on clinical judgment outside these parameters.

Questions worth asking your provider

• Given my health history, am I a good candidate? What are my specific contraindications?
• What are realistic expectations for my situation — not the trial averages, but for someone with my metabolic profile?
• How will we monitor for side effects, and what are the stopping criteria?
• What happens if I need to stop — for surgery, pregnancy, or financial reasons? What's the plan?
• What lifestyle changes should accompany the medication for best outcomes?
• How long do you expect I'd need to be on this medication?

Managing expectations realistically

Semaglutide is a powerful tool, but it's not a cure. The most durable results in the clinical literature came in patients who also maintained dietary changes and physical activity. Patients who used the reduced-appetite window created by the medication to build new eating habits and exercise patterns tended to fare better after eventual dose reduction or cessation.

Muscle mass protection also deserves emphasis. Multiple experts recommend pairing semaglutide therapy with a protein-prioritized diet and a consistent resistance training routine. This isn't optional for long-term health outcomes — it's central to them.

Monitoring during treatment

Responsible prescribing typically includes baseline labs (HbA1c, lipid panel, kidney function, liver enzymes), regular follow-up appointments, monitoring of weight, blood pressure, and heart rate, and screening for GI complications. Some providers also monitor body composition to track lean mass preservation over time.

If you're comparing GLP-1 options and want to understand tirzepatide's dual GIP/GLP-1 mechanism, SURMOUNT trial data, and how it stacks up head-to-head against semaglutide, see our full guide: Tirzepatide (Mounjaro/Zepbound) Explained.

For more on how peptides work in the body more broadly — including topical peptides studied for entirely different purposes — see our guide on GHK-Cu and the science of skin-focused copper peptides. The pharmacology is very different from GLP-1 agonists, but the underlying principle — engineered peptides targeting specific receptors — is the same.